The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | Sequential therapy with teclistamab after failure of BCMA-directed CAR-T & the value of bispecifics
Lukas Scheller, MD, University of Würzburg, Würzburg, Germany, highlights the value of bispecific antibodies as a treatment option for patients with multiple myeloma who relapse after BCMA-targeted CAR-T therapy, and summarizes a study which evaluated sequential therapy with teclistamab following failure of BCMA-directed CAR-T. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
